Objectives: Since resistance of Mycobacterium tuberculosis (Mtb) partially derives from efflux pumps (EPs) in the plasma membrane, the current study evaluates EPs in Mtb exposed to rifampicin in the presence of the EP inhibitor verapamil, within a macrophage environment.
Introduction
TB, an infectious disease caused by members of the Mycobacterium tuberculosis (Mtb) complex, caused 1.4 million deaths worldwide in 2015, with estimates of 10.4 million new cases. In 2015, there were 480 000 new cases of MDR-TB and an additional 100 000 people with rifampicin-resistant TB (RR-TB) who were also newly eligible for MDR-TB treatment. 1 Current TB treatment consists of an initial intensive phase with isoniazid, rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of isoniazid and rifampicin. In MDR-TB cases, a treatment consisting of other drugs, such as streptomycin, terizidone and a fluoroquinolone (levofloxacin or ofloxacin) has been proposed. 2 Patients with XDR-TB (i.e MDR-TB with additional resistance to any fluoroquinolone and an injectable second-line drug) should be sent to a reference centre for individualized regimens with reserved drugs, which comprise capreomycin, moxifloxacin, para-aminosalicylic acid and ethionamide. 3, 4 The MDR and XDR Mtb phenotypes are mainly caused by sequential mutations in specific chromosomal genes, related to the mechanisms of rifampicin and isoniazid and other drugs. However, the genetic basis of these two and other anti-TB resistant drugs are not fully understood. In the case of some resistant bacilli, the classic mutations related to specific drug resistance are not present suggesting other mechanisms are causing the resistance phenotype. 5 Sequence analysis of the Mtb genome showed multiple efflux pumps (EPs) 6, 7 which encode membrane proteins capable of actively transporting a broad range of compounds, including drugs. EP activities have been linked with the efflux of anti-TB drugs, such as isoniazid, rifampicin and ethambutol. 8, 9 Among the leading families of EPs, five are the most frequently mentioned in relation to mycobacteria: the resistance nodulation division (RND) family, the small drug multiresistance (SMR) family, the major facilitator superfamily (MFS), the multidrug and toxic compound extrusion (MATE) family and the ATP binding cassette (ABC) family. Combined with anti-TB drugs, EP inhibitors have been tested to increase the effectiveness of anti-TB drugs by inhibiting their efflux from the intrabacillary environment. Antagonists of transmembrane electrochemical potential and calcium channels, such as verapamil, have been tested in vitro and they proved to be good synergistic drug candidates for TB treatment. 9, 11 A relationship between EPs and the ability of Mtb to overcome oxidative stress within macrophages has been reported. 12 As an EP inhibitor, verapamil may reduce tolerance to anti-TB drugs (isoniazid and rifampicin) and promote the death of mycobacteria in a macrophage environment, because it retains the drug for a longer time inside the bacilli. 6, 11, 12 The macrophage model, which attempts to mimic the conditions in humans at the cell level, proved to be useful for studying the effect of drug combinations on Mtb. The model provides more data than in vitro models based on culture assays, such as drug penetration and the interaction between drugs inside macrophages. 13, 14 Moreover, studies involving Mtb macrophage infection may be of great help in understanding the mechanisms of bacillus resistance and immune response. The current analysis evaluates the regulation of EP genes in Mtb exposed to the rifampicin/verapamil combination, inside the macrophage environment. 
Materials and methods

Mtb
MICs
MICs of rifampicin and verapamil alone were determined using a resazurin microtitre assay plate method 15 and the activity of rifampicin/verapamil was evaluated by Caleffi-Ferracioli et al.
11 using a resazurin drug combination microtitre assay.
THP-1 cell culture
Human acute monocytic leukaemia cell line THP-1 (ATCC TIB-202) was maintained in DMEM-6429 (Sigma-Aldrich, St Louis, MO, USA) containing a 10% (v/v) FBS and 100 U/mL penicillin/streptomycin mixture (SigmaAldrich). Cells were incubated at 37 C in 5% CO 2 . THP-1 cells were calculated by trypan blue (Sigma-Aldrich) exclusion. When exponential cell growth was achieved, a concentration of 5%10 5 cells/mL was seeded into two 24-well plates (one for samples and one for the Mtb growth control) and 100 nM phorbol-12-myristate-13-acetate (PMA) (Sigma-Aldrich) was added. The plates were incubated until they reached macrophage differentiation (12 h at 37 C in 5% CO 2 ). The supernatant was then discarded and PMA was added again at the same concentration (100 nM). Incubation was continued for an additional 4 days at the same temperature and atmosphere conditions. Macrophage differentiation was checked by microscopy and macrophages were washed once with 1 mL of supplemented DMEM, without the penicillin/streptomycin mixture.
Infection of THP-1 cells with Mtb
Mtb H 37 Rv growth was centrifuged at 2880 g for 10 min and the bacterial pellet was shaken for 45 s with beads and suspended in DMEM. Single-cell suspension was checked by Ziehl-Neelsen stain.
The bacterial concentration was adjusted to OD 600 " 0.8-1.0 in a Hitachi U-1100 spectrophotometer (Hitachi, Tokyo), which corresponds to a concentration of 10 7 cfu/mL. The sample was diluted until a concentration of 5%10 5 cfu/mL was obtained.
The THP-1 macrophages in the two 24-well plates (assay and control) were infected with 5%10 5 cfu/mL of Mtb, which corresponds to a model of infection (MOI) of 1:1, and incubated for 3 h at 37 C in 5% CO 2 . Infected macrophages were washed three times with PBS to remove excess bacteria.
Two wells of the control plate containing the infected THP-1 macrophages at an MOI of 1:1 were lysed with 0.1% Triton (Sigma-Aldrich) for infection control. Lysed wells were plated onto OADC-supplemented Middlebrook 7H11 agar (Difco Laboratories) and incubated for 15 days at 37 C to determine cfu/mL. The other wells of both plates containing the infected macrophages were incubated with DMEM containing 10% (v/v) FBS without antibiotics, at 37 C in 5% CO 2 for 72 h, so that Mtb would grow inside the macrophages.
Drug exposure
After incubation of Mtb growth inside the macrophages (corresponding to time 0 h), the infected macrophages were rinsed with PBS, lysed with 0.1% Triton and plated on OADC-supplemented Middlebrook 7H11 agar. At the same time, rifampicin and verapamil alone and combined were added at 0.25 % MIC for verapamil (31.25 mg/L) and 0.5 % MIC for rifampicin (0.0015 mg/L) 11, 16 in a 24-well plate and incubated at 37 C for 24 and 72 h. Further, each well was washed three times with 1.0 mL of PBS (pH 7.4) and 0.1% Triton was added. Lysed macrophages of two control wells were plated on OADC-supplemented Middlebrook 7H11 agar and infected macrophages from the other wells were used for the study of EP gene regulation. All experiments were carried out in triplicate, on different days.
Gene regulation study
Total RNA was extracted in two time-independent experiments and purified using the RNeasy Mini Kit Plus (QIAGEN Biotechnology, Valencia, CA, USA), following the manufacturer's instructions. Quantity assessment was performed using a Qubit 2.0 fluorimeter (Invitrogen, Carlsbad, CA, USA). Synthesis of the first cDNA was carried out by random primer total RNA using SuperScript III Reverse Transcriptase (Invitrogen), with modifications by Bowler et al. 17 Quantitative PCR was performed using SYBR green PCR master mix (Applied Biosystems, Foster City, CA, USA) in the StepOne TM Real-Time PCR System. The EP-specific primers are listed in Table 1 .
Melting curves were assessed; samples were run in triplicate and the 16S rRNA (rrs) gene was used to normalize all reactions. A negative control was included in all experiments. A reference assay was conducted in the absence of any drug. The relative quantification of target gene regulation was calculated by the 2 #DDCT method. 20 Data analysis was performed by one-way test with BioEstat 5.0 software, 21 followed by Tukey's post hoc test (significant at P , 0.05). Figure 1 displays the experiment.
Results
MOI 1:1 was performed for the two drugs alone (rifampicin and verapamil) and their combination to determine Mtb survival inside the macrophages at the time of infection (without drugs, time 0 h) and at 24 and 72 h of drug exposure. At time 0 h, the Mtb count on Middlebrook 7H11 agar was 5.7%10
5 cfu/mL ( Figure 2) ; at 24 and 72 h, the counts were 5.4%10 5 cfu/mL and 5.1%10 5 cfu/mL, respectively.
After 24 h of rifampicin exposure (Figure 3a ), 10 EP genes were up-regulated when compared with the control, with the exception of Rv1258c (MFS family). After exposure to verapamil, eight EP Intramacrophage M. tuberculosis efflux pump regulation JAC genes were up-regulated, with the exception of Rv1258c, Rv2459 and Rv1217c (MFS, MFS and ABC family, respectively). Rifampicin/ verapamil induced down-regulation of 54.5% (6/11) of the EP genes. However, in the case of the Rv1456c, Rv3065, Rv1217c and Rv2459 genes (ABC, SMR, ABC and MFS family, respectively), a significant up-regulation (P , 0.01 for Rv1456c and P , 0.05 for Rv3065, Rv1217c and Rv2459) was observed.
At 72 h (Figure 3b) , most of the studied EP genes (10/11) were upregulated after exposure to rifampicin, with the exception of Rv1457c (ABC family). After exposure to verapamil, down-regulation of most genes (8/11) was observed, with the exception of Rv1456c, Rv2459 and Rv1217c (ABC, MFS and ABC families, respectively). Finally, after exposure to rifampicin/verapamil, down-regulation of the majority of genes (8/11) was observed, with the exception of Rv1218c, Rv1457c and Rv1819c (ABC family).
Discussion
Intramacrophage growth is a hallmark of Mtb during TB development. The bacilli face the most varied adversities inside the host Canezin et al.
cell, such as nutritional deficiency, acidic environment, hypoxia, oxidative stress and others, which influence TB development. Similarly, different alterations in the bacilli cause different consequences, mainly affecting susceptibility to anti-TB drugs. 22, 23 Owing to the difference in environments of Mtb during the development of the disease, it is highly relevant to not only investigate the resistance mediated by EP expression in the in vitro extracellular (extramacrophage) environment, but also in the bacilli within the intramacrophage environment. Recently, our research group reported extramacrophage studies involving EP gene regulation 11 and fluorimetry assays 24 to evaluate the Mtb inhibitory activity of rifampicin, when combined with verapamil, on EP-mediated resistance. These studies showed rifampicin MIC reduction and down-regulation of some EP genes when Mtb was exposed to rifampicin/verapamil in an extramacrophage environment, suggesting an increase in rifampicin activity when combined with verapamil. Previous results motivated us to continue studying rifampicin/verapamil in Mtb and compare EP gene regulation in Mtb in intramacrophage and extramacrophage environments.
First, the number of viable intramacrophage bacilli was evaluated for gene regulation studies in internalized Mtb. We observed a non-significant decrease in cfu/mL at 24 h, after 72 h of drug exposure. The above demonstrated that the number of live bacilli was consistent with the MOI for gene regulation studies of Mtb internalized in macrophages. 13 Helguera-Repetto et al. 25 observed that, after 6 h of macrophage exposure to Mtb, 100% of THP-1 cells were infected; after 48 h, the Mtb population remained the same inside the macrophage; a fact consistent with our results. Since, in the current study, 72 h of Mtb internalization did not reveal multiplication or significant bacillus death in the macrophage environment, the experiment was carried out.
Eleven EP genes from the ABC, MFS and SMR families, associated with resistance to rifampicin and other drugs, 7, 9, 10 were chosen to analyse the profile of EP gene regulation in intramacrophage Mtb. Mtb gene regulation was previously studied by Caleffi-Ferracioli et al., 11 at the same laboratory, under extramacrophage conditions. It should be emphasized that the two studies had one different time of drug exposure. Caleffi-Ferracioli et al. 11 carried out EP regulation analyses at 16 and 72 h of drug exposure, whilst, in the current study, times of 24 and 72 h were chosen according to previous studies by our group, when times of 16 and 24 h failed to present any significant difference based on time-kill curves, since this interval of time encompasses the bacilli's first cellular division. Further, we believe that comparative studies should be performed.
Rifampicin penetrates Mtb and macrophage cells, including phagolysosomes, passively. It binds to the bacterial DNAdependent RNA polymerase, blocks the protein synthesis and causes bacillus death. 26 We could expect bacillus EP up-regulation in the presence of rifampicin alone, in the first hours, once the bacilli try to expel the rifampicin.
In the current study, after 24 h of exposure to rifampicin alone, most of the Mtb EP genes were up-regulated, with the exception of Rv1258c (MFS family). We could observe different EP regulation patterns by the bacilli exposed to rifampicin alone in intramacrophage and extramacrophage studies, 11 although the Rv1258c gene was down-regulated in both environments, extramacrophage and intramacrophage. In contrast, Jiang et al. 19 reported up-regulation of Rv1258c in Mtb H 37 Rv exposed to rifampicin alone, in an in vitro extramacrophage environment. However, comparing the above with the current study is rather difficult, since time exposure was not specified by the authors.
Down-regulation of three EP genes, Rv1258c, Rv1217c and Rv2459, from the MFS, ABC and MFS families, respectively, was observed at 24 h of exposure to verapamil alone. Caleffi-Ferracioli et al. 11 showed down-regulation of all EPs studied, revealing a marked difference between Mtb EP regulation in extramacrophage and intramacrophage environments.
The 24 h rifampicin/verapamil Mtb exposure results showed variable EP gene regulation patterns, with up-regulation of Rv1456c, Rv3065, Rv1458c, Rv1217c and Rv2459 genes and downregulation of Rv1218c, Rv1457c, Rv1819c, Rv2846, Rv1258c and Rv1410c genes. The only similarity between extramacrophage and intramacrophage studies was observed with three EP genes, Rv1217c, Rv2459 and Rv1410c. Genes Rv1217c (ABC family) and Rv2459 (MFS family) were statistically up-regulated, whereas the Rv1410c gene (MFS family) was down-regulated in both studies.
According to Ramon-Garcia et al., 27 the Rv1410c gene is involved in the maintenance of normal growth characteristics and in the oxidative stress response. Further, Martinot et al. 28 corroborated the above result by reporting that deficiency of the protein coded by the Rv1410c gene caused a high degree of bacterial attenuation in a mouse model infection. These two studies may demonstrate that Rv1410c down-regulation by the bacilli, observed in a macrophage environment, may induce regulation of other genes, such as Rv1217c and Rv2459 (at 24 h of exposure), in an attempt to survive in the intramacrophage environment.
An initial EP gene down-regulation in Mtb exposed to rifampicin/verapamil for 24 h has been reported in an intramacrophage environment, when compared with rifampicin alone. The difference in EP regulation requires further studies to better understand the true activity of verapamil in this condition.
The 72 h drug exposure results revealed a different Mtb EP gene regulation pattern. Exposure to rifampicin alone induced upregulation of 10 Mtb EP genes in the macrophage environment. However, five of them (Rv1458c, Rv1218c, Rv1819c, Rv2846 and Rv1217c), four from the ABC family and one from the MFS family, had significant up-regulation. In previous studies, carried out in an extramacrophage environment, the up-regulation of EP genes 11, 30 was also observed in the bacilli exposed to rifampicin alone.
Inside phagolysosomes, Mtb is exposed to reactive oxygen species, acidity and other chemical agents produced by macrophages, 23 which may direct the regulation of other genes, including other EP genes, in order to survive inside the macrophages. This seems to happen when we compare EP gene regulation at 24 and 72 h, with a decrease in regulation levels as time passes for exposure to rifampicin alone. A similar interpretation can be made for low Mtb EP regulation inside the macrophage when compared with extramacrophage studies by CaleffiFerracioli et al. 11 and others. 31, 32 Exposure to verapamil alone induced the bacilli to lower EP regulation at 72 h when compared with 24 h. Verapamil acts on Results were normalized to 16S rRNA and the relative regulation was calculated using the 2 #DDCT method. *P , 0.01 and **P , 0.05 compared with Mtb control growth in the absence of drugs. RIF, rifampicin; VP, verapamil; C, control.
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two pathways that directly affect the survival of Mtb inside the macrophage. The first one involves the inhibition of Ca 2! pumps located at the phagolysosome membrane, increasing acidity and inducing better activity of hydrolases inside the phagolysosome, leading to mycobacterial death. 31 The second pathway is related to the inhibition of EPs of the bacillus membrane, which increases the concentration of rifampicin inside the bacilli and improves the efficacy of the drug. 32 Although other authors have demonstrated the inhibitory activity of verapamil against EPs, mainly of the ABC family, the present study demonstrated the inhibition of EPs from other families too, such as MFS and SMR, to a greater or lesser extent, according to the exposure time and the EP gene studied.
The evaluation of EP gene regulation at 72 h of exposure to rifampicin/verapamil showed down-regulation of most EPs, with the exception of Rv1218c, Rv1457c and Rv1819c. It was expected that for rifampicin/verapamil the bacilli were at risk of death, which would result in an up-regulation of EP genes in an attempt to survive by expelling rifampicin. This effect was observed with Rv1218c, Rv1457c and Rv1819c at 72 h of exposure. However, it appears that rifampicin/verapamil was effective, to a point, in causing down-regulation of most EPs when compared with rifampicin alone. The above was also reported in an extramacrophage environment by Caleffi-Ferracioli et al.
11
It should be emphasized that, at 72 h of exposure to rifampicin/ verapamil, the Mtb showed down-regulation of most EP genes (eight) when compared with exposure to rifampicin alone, including statistically significant results for Rv2846, Rv1258c and Rv1458c. However, the EPs Rv1218c, Rv1457c and Rv1819c (all from the ABC family) were statistically up-regulated. Studies in the extramacrophage environment 11 showed the same pattern of gene regulation for most EPs under analysis, with the exception of Rv1218c, Rv1457c, Rv1819c and Rv2846.
EP down-regulation was reported after exposure to rifampicin/ verapamil at 72 h when compared with EP gene regulation at 24 h. Results agreed for five EPs (Rv3065, Rv1458c, Rv2846, Rv1258c and Rv1410c) in the extramacrophage study. 11 The above results, associated with other research on reduction of MIC when Mtb is exposed to rifampicin/verapamil, 11, 24 reinforce the fact that verapamil may enhance rifampicin activity, ensuring more effectiveness in therapy for TB caused by Mtb involving resistance mediated by EPs.
Conclusions
The current study demonstrated that rifampicin/verapamil decreased the regulation of several EP genes in Mtb inside the macrophage environment. This combination would undoubtedly aid in the therapy against Mtb MDR. Additional in vivo studies would highlight the activity of rifampicin/verapamil against the bacilli in in vitro extramacrophage and intramacrophage environments.
